Cordis Corporation Release: Economic Model Presented at ISPOR 2011 Suggests That the Use of EXOSEAL Vascular Closure Device May Result in Important Cost Savings for U.S. Hospitals

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Results from a Cordis analysis presented at the 14th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) congress in Madrid indicates use of EXOSEALTM Vascular Closure Devices in patients undergoing percutaneous coronary interventions (PCI) may result in important cost-savings for U.S. hospitals, as compared to combined use of ANGIO-SEALTM, MYNXTM, PERCLOSETM, and STARCLOSETM Vascular Closure Devices*(VCDs).